Business
TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Future Market Opportunities
WALTHAM, Mass., Dec. 03, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced the Company will host a virtual key opinion leader (KOL) event to discuss updated data from the ALLOHA™ Phase 1 trial being presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition and the fu
About this update from Tscan Therapeutics, Inc.
[{"type":"image","alt":"TScan Therapeutics, Inc.","displaySize":"","headline":null,"caption":"TScan Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":88,"url":"https://media.zenfs.com/en/globenewswire.com/c363c98946cf506a90ed1ea98d7db5fd"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/oJd2gbDue06Bt1BDI6AStQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyMztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/c363c98946cf506a90ed1ea98d7db5fd","width":300,"height":88}},"lazy":false},{"type":"text","content":"WALTHAM, Mass., Dec. 03, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced the Company will host a virtual key opinion leader (KOL) event to discuss updated data from the ALLOHA™ Phase 1 trial being presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition and the future market opportunity for its heme program. The virtual event will take place on Monday, December 8, at 8:00 a.m. ET.","length":619,"tagName":"p"},{"type":"text","content":"The event will provide an in-depth review of the poster presented at the ASH Annual Meeting, including two-year relapse data on initial patients from TScan’s ongoing ALLOHA Phase 1 trial evaluating TSC-101 in patients with heme malignancies undergoing allogeneic hematopoietic cell transplantation (HCT). The Company will discuss its improved commercial-ready manufacturing process that has recently been implemented in the ALLOHA Phase 1 trial and will be used in the upcoming pivotal trial scheduled to start in the second quarter of 2026. The Company will also review the unmet medical need and potential market opportunity for TSC-101 and follow-on product candidates.","length":672,"tagName":"p"},{"type":"text","content":"Featured speakers include:","length":26,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Ran Reshef, M.D., M.Sc., Director of Translational Research, Blood and Marrow Transplantation Program, Director of the Cell Therapy Program, Columbia University Irving Medical Center","length":182,"tagName":"p"}]},{"val":[{"type":"text","content":"Gavin MacBeath, Ph.D., Chief Executive Officer, TScan Therapeutics",...